(Q39056302)

8 September 2017

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity (English)

1 reference

8 September 2017

1 reference

ChEBI release 2020-05-28

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Y. Lynn Wang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

S Cheng

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

J Ma

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

P Lu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

J P Leonard

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

M Coleman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

M Liu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

J J Buggy

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

R R Furman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

publication date

25 November 2013

1 reference

8 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

649-657

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24270740%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2013.358

8 June 2020

exact match

0 references

cites work

New strategies in the treatment of mantle cell lymphoma.

1 reference

12 December 2020

Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?

1 reference

12 December 2020

Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.

1 reference

12 December 2020

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

1 reference

12 December 2020

Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.

1 reference

12 December 2020

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

1 reference

12 December 2020

Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia.

1 reference

12 December 2020

B cell antigen receptor signaling 101.

1 reference

12 December 2020

CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells

1 reference

12 December 2020

Chronic lymphocytic leukemia

1 reference

12 December 2020

Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins

1 reference

12 December 2020

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

1 reference

12 December 2020

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

12 December 2020

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

1 reference

12 December 2020

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

1 reference

12 December 2020

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

1 reference

12 December 2020

Early events in B cell activation

1 reference

12 December 2020

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia

1 reference

12 December 2020

A proposal regarding reporting of in vitro testing results

1 reference

12 December 2020

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

1 reference

12 December 2020

In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

B cell signaling and fate decision.

1 reference

12 December 2020

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

1 reference

12 December 2020

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

1 reference

12 December 2020

1 reference

12 December 2020

Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy

1 reference

12 December 2020

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

1 reference

12 December 2020

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

1 reference

12 December 2020

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

1 reference

12 December 2020

Mechanisms of B-cell lymphoma pathogenesis

1 reference

12 December 2020

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes

1 reference

12 December 2020

Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals

1 reference

12 December 2020

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

1 reference

12 December 2020

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

1 reference

12 December 2020

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro

1 reference

12 December 2020

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells

1 reference

12 December 2020

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

1 reference

12 December 2020

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

1 reference

12 December 2020

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma

1 reference

12 December 2020

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia

1 reference

12 December 2020

Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma.

1 reference

12 December 2020

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

1 reference

12 December 2020

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

1 reference

12 December 2020

SYK inhibition and response prediction in diffuse large B-cell lymphoma

1 reference

12 December 2020

Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles

1 reference

12 December 2020